Aptose Biosciences Inc. logo
Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia
October 19, 2020 07:00 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Inc. logo
Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia
June 29, 2020 07:01 ET | Aptose Biosciences, Inc.
Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML Phase 1a/b study in B-cell malignancies continues through dose escalation SAN DIEGO and TORONTO,...
Aptose Biosciences Inc. logo
Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association
June 12, 2020 07:00 ET | Aptose Biosciences, Inc.
Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies Plasma from CG-806 treated patients completely inhibited...
Aptose Biosciences Inc. logo
Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020
April 27, 2020 09:00 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose Reports Results for the Fourth Quarter and Full Year 2019
March 10, 2020 16:02 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 10, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Inc. logo
Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)
October 10, 2019 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Inc. logo
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
July 16, 2019 07:05 ET | Aptose Biosciences, Inc.
 – CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML  –  – APTO-253 MYC inhibitor being developed for the...
Aptose Biosciences Inc. logo
Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association
June 14, 2019 07:00 ET | Aptose Biosciences, Inc.
– CG-806 safely and durably suppressed tumor growth in preclinical models – SAN DIEGO and TORONTO, June 14, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:...
Aptose Biosciences Inc. logo
Aptose Presents New Preclinical Data on CG-806 and APTO-253 at the 2019 AACR Annual Meeting
April 01, 2019 13:00 ET | Aptose Biosciences, Inc.
Pan-FLT3/pan-BTK inhibitor CG-806 Demonstrates Significant and Superior Potency Against Primary Cells Across AML Types –  MYC Inhibitor APTO-253 Potently Kills Hematologic Cell Lines; Mechanism of...
Aptose Biosciences Inc. logo
Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806
March 25, 2019 07:02 ET | Aptose Biosciences, Inc.
– CG-806 highly potent, oral, non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – Phase 1 trial in relapsed or refractory...